- Home
- STOK
as 03-25-2025 4:00pm EST
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | BEDFORD |
| Market Cap: | 556.7M | IPO Year: | 2019 |
| Target Price: | $23.83 | AVG Volume (30 days): | 742.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.65 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.22 - $17.58 | Next Earning Date: | 03-18-2025 |
| Revenue: | $36,555,000 | Revenue Growth: | 316.34% |
| Revenue Growth (this year): | -12.4% | Revenue Growth (next year): | -19.79% |
Stock Insider Trading Activity of Stoke Therapeutics Inc. (STOK)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | Mar 18 '25 | Sell | $8.47 | 7,217 | $61,238.19 | 63,962 | |
| Kaye Edward M. MD | STOK | Director | Mar 18 '25 | Sell | $8.47 | 19,289 | $163,672.83 | 148,253 | |
| Allan Jonathan | STOK | GENERAL COUNSEL & CORP SEC | Mar 18 '25 | Sell | $8.47 | 4,211 | $35,731.37 | 33,510 |
Latest Stoke Therapeutics Inc. News
STOK Breaking Stock News: Dive into STOK Ticker-Specific Updates for Smart Investing
Simply Wall St.
4 days ago
Earnings Beat: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Investopedia
8 days ago
Stoke Therapeutics Stock Slips as CEO Steps Down
Zacks
8 days ago
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates
BioPharma Dive
8 days ago
Stoke CEO exits; Medicare drug price talks advance
MT Newswires
8 days ago
Stoke Therapeutics CEO Edward Kaye Steps Down; Interim CEO Named
Business Wire
8 days ago
Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Business Wire
8 days ago
Stoke Therapeutics Announces CEO Transition
Zacks
9 days ago
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Compare STOK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "STOK Stoke Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.